


## Antiproliferative agent-10

<b>Cat. No.:</b>	HY-150966
<b>Molecular Formula:</b>	C <sub>35</sub> H <sub>36</sub> Cl <sub>2</sub> N <sub>7</sub> PRu
<b>Molecular Weight:</b>	757.66
<b>Target:</b>	Mitochondrial Metabolism
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Antiproliferative agent-10 (compound 8) is an anti-tumour ruthenium(II)-tris-pyrazolylmethane complex that inhibits the growth of cancer cells by inhibiting mitochondrial calcium uptake <sup>[1]</sup> .								
<b>In Vitro</b>	<p>Antiproliferative agent-10 (compound 8) (2-20 μM, 72 h) has some anti-cancer cell proliferative activity and effectively induces apoptosis in HCT116 cells<sup>[1]</sup>.</p> <p>Antiproliferative agent-10 (15 μM, 24 h) shows HCT116 cell survival rates of 93% to 97% and ruthenium content of cell was 59.4 ng/10<sup>6</sup> cells, so that it can accumulate efficiently in the cells and promote their biological activity<sup>[1]</sup>.</p> <p>Antiproliferative agent-10 (10-32 μM, 5 h) can cause mitochondrial depolarization in a concentration-dependent manner and inhibit mitochondrial calcium uptake<sup>[1]</sup>.</p> <p>Antiproliferative agent-10 can inhibit the formation and growth of spheroids of HCT116 cells with an IC<sub>50</sub> value of 12.1 μM<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)</td> </tr> <tr> <td>Concentration:</td> <td>2-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC<sub>50</sub> values of 10, 15, 10, 8 and 6.6 μM, respectively.</td> </tr> </table>	Cell Line:	MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)	Concentration:	2-20 μM	Incubation Time:	72 hours	Result:	Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC <sub>50</sub> values of 10, 15, 10, 8 and 6.6 μM, respectively.
Cell Line:	MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)								
Concentration:	2-20 μM								
Incubation Time:	72 hours								
Result:	Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC <sub>50</sub> values of 10, 15, 10, 8 and 6.6 μM, respectively.								

### REFERENCES

[1]. Jakub Cervinka, et al. Ruthenium(II)-Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis. J Med Chem. 2022 Aug 1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA